Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 04, 2026, titled "Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity".
Zydus Lifesciences Limited Press Release Aug 04 2026
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced final approval from the USFDA for Indocyanine Green for Injection, which includes a period of exclusivity for competitive generic therapies. The product is an optical imaging agent used in various surgical procedures and will be manufactured at Zydus' facility in Gujarat. This approval enhances Zydus' portfolio of complex injectables and reflects their commitment to high standards in healthcare solutions. The press release aims to inform investors and the exchange about this significant regulatory milestone.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 01 2026
- Zydus Lifesciences Limited Press Release Jul 23 2026
- Zydus Lifesciences Limited Press Release Jul 03 2026
- Press Release May 28 2026
- Zydus Cancer Hospital, Ahmedabad marks 200+ Stereotactic Radiotherapy (SRT)/SRS for Brain Tumours
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 11 2026
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
- Zydus Lifesciences Limited Press Release Aug 21 2026
- Zydus Lifesciences Limited Press Release Aug 31 2026
- Zydus Lifesciences Limited Press Release Sep 26 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences